Filing Context and Reporting Period
The provided filing is Gemphire Therapeutics Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed March 15, 2019. The request metadata identifies “Metavia Inc.” and “2018 Q4,” but the filing text clearly identifies Gemphire Therapeutics Inc.; this entity mismatch should be verified. The filing includes unaudited quarterly data for the fourth quarter of 2018.
Gemphire was a clinical-stage biopharmaceutical company with no approved products or revenue. Its primary candidate, gemcabene, was being developed for dyslipidemia and NAFLD/NASH, initially emphasizing orphan indications including HoFH, FCS and FPL.
Financial Performance and Position
| Metric | 2018 | 2017 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| General and administrative expense | $8.5 million | $10.4 million | Down $1.9 million |
| Research and development expense | $14.3 million | $22.7 million | Down $8.4 million |
| Total operating expenses | $22.8 million | $33.1 million | Down $10.3 million |
| Operating loss | $22.8 million | $33.1 million | Improved $10.3 million |
| Net loss | $23.6 million | $33.4 million | Improved $9.8 million |
| Basic and diluted loss per share | $1.71 | $3.23 | Improved |
| Cash used in operating activities | $21.9 million | $26.9 million | Improved $5.0 million |
| Cash and cash equivalents at year-end | $19.0 million | $18.5 million | Up $0.5 million |
| Total liabilities | $11.9 million | $15.1 million | Down $3.2 million |
| Stockholders’ equity | $7.8 million | $3.9 million | Up $3.8 million |
The company reported no income taxes because it had incurred operating losses and maintained a full valuation allowance against deferred tax assets. The filing does not provide a meaningful operating margin because the company generated no revenue; operating losses equaled operating expenses.
Financing activities provided $22.4 million in 2018, primarily from a follow-on offering of 3,592,858 shares at $7.00 per share, which generated approximately $23.0 million of net proceeds. Cash increased by $0.5 million during the year.
At December 31, 2018, the company reported $9.4 million of current term-loan liabilities. The Silicon Valley Bank term loan was prepaid in full on January 28, 2019, including approximately $8.9 million of principal and approximately $1.0 million of interest and fees. No material off-balance-sheet arrangements were reported.
Fourth-Quarter 2018 Results
Fourth-quarter operating expenses were $3.3 million, consisting of $1.5 million of general and administrative expense and $1.8 million of research and development expense. Fourth-quarter net loss was $3.7 million, or $0.26 per basic and diluted share. The quarter included approximately $1.6 million of workforce-reduction charges, largely recognized in the third quarter but associated with the 2018 reduction in force.
Material Changes Versus the Prior Comparable Period
- Net loss declined 29% from $33.4 million to $23.6 million, primarily because clinical activity and related research and development spending decreased.
- Research and development expense declined 37%, reflecting reduced clinical-trial activity after the FDA delayed the company’s Phase 3 plans.
- General and administrative expense declined 19%, principally because 2017 included larger separation costs related to the former chief executive officer.
- Cash used in operations declined 19%, although operating cash burn remained substantial.
- The company raised approximately $23.0 million net through its February 2018 follow-on offering, increasing shares outstanding to 14,265,411 at year-end from 10,633,042 at December 31, 2017.
- The company reduced its workforce by five employees, approximately 33% of its workforce at the time, and recorded approximately $1.6 million of related severance and accelerated stock-compensation charges.
- The Pfizer license was amended to extend the deadline for first commercial sale by three years, to April 2024.
Development, Outlook, Risks and Unusual Items
- FDA partial clinical hold: The FDA did not lift the hold limiting human studies longer than six months after reviewing the company’s two-year rodent carcinogenicity studies. Additional preclinical studies were requested, including a 13-week PPAR-alpha knockout mouse study and PPAR transactivation assays. The company expected to submit the additional data in the fourth quarter of 2019. Phase 3 planning and an End-of-Phase 2 meeting were dependent on lifting the hold.
- Clinical safety concern: An investigator-initiated pediatric NAFLD study was halted after six patients enrolled because of unanticipated increases in ALT and liver fat in early participants. Compliance was compromised, and the risk of increased liver fat remained unknown. The company stated that the finding could affect future NAFLD development.
- FPL program: The adult FPL study continued after interim review, completed enrollment of five patients in the fourth quarter of 2018, and had top-line data expected in the second quarter of 2019.
- Clinical efficacy: The company reported statistically significant primary-endpoint results in its HoFH, hypercholesterolemia and severe hypertriglyceridemia Phase 2b trials. Reported examples included a 17% LDL-C reduction versus 5% for placebo in ROYAL-1 and a 47.32% median triglyceride reduction versus 27.30% for placebo in the 600 mg group in INDIGO-1.
- Liquidity and going concern: Management stated that year-end cash was expected to fund operations only into the third quarter of 2019. The auditor and management disclosed substantial doubt about the company’s ability to continue as a going concern. Additional financing was required, with no committed external funding source.
- Strategic alternatives: In December 2018, the board formed a committee and retained Ladenburg Thalmann to evaluate strategic alternatives. The filing cautioned that no transaction was assured and that the process could increase costs, disrupt operations or fail to create stockholder value.
- Pfizer obligations: The license provides for up to $37 million of milestone payments and tiered royalties ranging from the high single digits to the mid-teens on future net sales. Pfizer may terminate if first commercial sale is not achieved by April 16, 2024.
- Other unusual items: Share-based compensation was $4.1 million in 2018. The company also recognized approximately $0.2 million of strategic-alternatives transaction costs and had no material legal proceedings reported.
Investor Verification Checklist
- Verify the issuer identity: the supplied metadata says Metavia Inc., while the filing is for Gemphire Therapeutics Inc.
- Confirm current liquidity after the January 2019 repayment of the SVB term loan, including the effect of approximately $1.0 million of interest and fees and approximately $0.8 million of accelerated debt-discount expense.
- Determine whether the company obtained additional financing after the filing date and whether it remained a going concern.
- Track the FDA’s response to the additional preclinical studies and whether the partial clinical hold was lifted.
- Review final results and safety findings from the pediatric NAFLD follow-up and adult FPL study.
- Assess whether the company completed a strategic transaction or otherwise preserved rights under the Pfizer license before the April 2024 commercial-sale deadline.
- Evaluate dilution from the 2018 equity offering, outstanding options and approximately 1.0 million outstanding warrants.
- Reconcile the company’s reported clinical efficacy claims with later controlled-trial, regulatory and safety outcomes.